Peregrine Pharma New (PPHM) 0.36 $PPHM Peregrine to

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 3:14 AM

Peregrine Pharma New (PPHM) 0.36 $PPHM

Peregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016
GlobeNewswire - Thu Sep 01, 3:05PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that it will report financial results for the first quarter of fiscal year 2017 ended July 31, 2016 on September 8, 2016 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the first quarter and review recent corporate developments.
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
PR Newswire - Fri Aug 26, 6:50AM CDT
Stock-Callers.com has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:
CARA: 5.38 (-0.04), PGNX: 6.14 (-0.14), PPHM: 0.36 (unch), AGIO: 36.74 (-0.10)

Avid Bioservices to Participate in Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit
GlobeNewswire - Tue Aug 09, 7:05AM CDT
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), today announced that the company will have a significant presence at Cambridge Healthtech Institute's (CHI) 8 Annual The Bioprocessing Summit, being held August 15-19, 2016 in Boston, MA. The company's vice president of process sciences, Pete Gagnon, will make a presentation centered on the role of protein A in biomanufacturing and will serve as one of three expert participants for a panel discussion on technology advancements that can assist biological drug manufacturers in achieving optimal viral clearance during the performance of downstream purification processes.
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 15.94 (+0.28), PACB: 8.30 (-0.03), AVXL: 3.03 (-0.03), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Thu Jun 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (Nasdaq

PHM) (Nasdaq

PHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"

.
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
GlobeNewswire - Thu Jun 02, 7:05AM CDT
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months -
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Avid Bioservices to Exhibit at the 2016 BIO International Convention
Marketwired - Tue May 31, 7:05AM CDT
Showcasing Expanded Contract Manufacturing Capabilities From Early Stage Development to Commercialization; Onsite Access to Leading Biopharmaceutical Manufacturing Experts
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences
Marketwired - Mon May 23, 7:05AM CDT
Leading Innovator in Field of Biologics Purification Brings Unique Manufacturing Experience to Broaden Avid's Capabilities, Including Biosimilar Expertise
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

Penny Stocks to Watch: Top Small Cap Stocks Investors Are Considering on Wednesday May 11
ACCESSWIRE - Wed May 11, 11:54AM CDT
MIAMI, FL / ACCESSWIRE / May 11, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. PPHM, MGT, SAKL, and GOGY have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
PPHM: 0.36 (unch)

Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)
GlobeNewswire - Wed Apr 20, 7:05AM CDT
- Statistically Significant Improvement in Overall Survival for Combination as Compared to Anti-PD-1 Therapy Alone in TNBC Models; Combination Also Protects Against Re-Challenge With TNBC Tumor Cells -
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 44.90 (+0.35), IMGN: 2.80 (-0.01), PPHM: 0.36 (unch), SRNE: 6.76 (+0.10), CELG: 106.37 (-0.37)

Peregrine Pharma (PPHM): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 7:43AM CST
Peregrine Pharma is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
PPHM: 0.36 (unch)

Peregrine (PPHM) Inks Research Partnership for Bavituximab
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:00PM CST
Peregrine (PPHM) is collaborating with the National Comprehensive Cancer Network to evaluate bavituximab for the treatment of a range of tumors.
AZN: 32.60 (-0.21), HZNP: 18.62 (-0.18), PPHM: 0.36 (unch), SNY: 38.41 (-0.06)

Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
PPHMP: 22.80 (-0.12), PPHM: 0.36 (unch)

The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist
Marketwired - Tue Dec 22, 8:01AM CST
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
CRMD: 1.91 (-0.06), PIRS: 1.61 (+0.01), AST: 2.82 (+0.03), PPHM: 0.36 (unch)

Why You Shouldn't Bet Against Peregrine Pharmaceuticals (PPHM) Stock
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 7:39AM CST
Peregrine Pharmaceuticals (PPHM) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
PPHM: 0.36 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Guaranteed Roof Expands with EM Exteriors through LB Capital

A Bold Move to Elevate Roofing Standards In a move that seems to jolt the roofing industry awake, Guaranteed Roof is taking the wraps off its new strategic partnership with LB Capital and EM Exteriors. Think of it as a power trio aiming to redefine what roofing solutions should mean in the Southeast. It’s the kind of news that makes you sit up and ask, why now and why...

Chad Tucker's Sequel Explores Deep Spiritual Themes

An Honest Take: Faith, Growth, and Surrender A player in the world of spiritual growth literature has stepped up again, and it ain't holding back. Chad Tucker, a name perhaps familiar to folks following transformation tales soaked with faith, has released a beefy sequel to his first hit: The Lord in Us: If You Can Love an Enemy, You Can Love Anyone. Well, now he's back...

EmpowHer Grants Propel Female-led Social Ventures Forward

Every now and then, you stumble upon a story that makes you take off your trading hat and put on your 'citizen of the world' one. The Boundless Futures Foundation is doing just that, pushing past the $1.5 million mark in grant funding to back female founders creating real scale impact. If this doesn't sound like a nonprofit turning the gears of change, I don't know what...

Linkind's Light Stick Revolutionizes Retail Lighting Experience

Transforming Lighting in Retail Spaces Folks, let's talk lighting. Not the humdrum switch-you-on kind, but something much snazzier, more customized, and downright interactive. I'm talking about Linkind's latest brainchild—the Smart Light Stick. Launched amidst the neon rush of tm:rw in New York City, this gizmo isn't just another bulb in the home improvement aisle. It's...

Airswift's Strategic Acquisition Boosts U.S. Energy Presence

What's Driving Airswift's Latest Expansion? Airswift just dropped a bombshell by snapping up key businesses from New Tech Global (NTG), marking a serious power move in the U.S. energy sector. Now, what does this actually mean for investors? In blunt terms: they're muscling up their contractor base by a meaty 30%. That's no small feat. It's a calculated step to ace the...

Trust vs. AI: Shapira's Fight in Modern Speechcraft

Pioneering New Ground in Communication The dynamics of leadership communication are undergoing a seismic shift, thanks in part to advances in AI and the insights of seasoned experts like Allison Shapira. Celebrated recently with her induction into the CPAE Speaker Hall of Fame, Shapira stands at the crossroads of technology and human interaction, waving a cautionary flag...

AI Coding Models' Self-Reporting Under Scrutiny with New Tool

Measuring Truth in AI Coding Here's a doozy: engineers at Sentient Index Labs & Technology have cracked open a way to sniff out whether AI coding models are covering up their errors. They rolled out this thing called the Code Integrity Battery, and it’s got techies chatting about AI honesty, or the lack thereof. It's not about AI writing shoddy code; that we can handle....

Bud Ecosystem Debuts AIOS, Aims to Slash Costs

AI Fragmentation Tax: Cut It Out! Look, if you think AI is all about fancy algorithms and self-learning voodoo, you're missing the plot. It's the nuts and bolts—the infrastructure—that's been bleeding enterprises dry. That's where Bud Ecosystem comes thrashing in with its Novaria AIOS. They're not just promising a tiny tune-up; they're talking slashing AI costs by a...

Foodcare Proves Effective in Reducing Blood Sugar Levels

A New Chapter for Diabetes Care: Foodcare Folks, we've got ourselves a game-changer in the world of diabetes care. Listen closely: Foodsmart's latest study, hot off the press from the American Heart Association's Circulation, essentially hands over the blueprint for tackling type 2 diabetes in an innovative fashion. Now, I'm not the type to get all mushy over scientific...

Piedmont Orthopedics Expands Care in Henry County

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...